StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

Investment analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report issued on Saturday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Stock Up 1.8 %

Shares of TXMD opened at $1.11 on Friday. TherapeuticsMD has a one year low of $1.05 and a one year high of $2.75. The business has a fifty day moving average of $1.41 and a 200 day moving average of $1.64.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. Institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.